Lonza Completes First GMP Batch at New Mammalian Manufacturing Portsmouth Facility

• Lonza has completed its first GMP product batch at its next-generation mammalian manufacturing facility in Portsmouth, US.

• This facility is designed to meet the increasing demand for small- to mid-scale volumes of mammalian-derived biologics and innovative therapies.

Lonza, a global development and manufacturing partner to the pharmaceutical, has announced the completion of its first GMP product batch at its newly developed mammalian manufacturing facility in Portsmouth, US. This achievement marks a significant milestone in the company’s ongoing efforts to meet growing market demand for biologics production.

The new facility, which leverages advanced process technologies, is designed to support the production of small- to mid-scale batches of mammalian-derived biologics. By using small-scale bioreactors, the facility offers greater flexibility, reduced capital investments, and lower operational costs, which are crucial for managing volume forecasting challenges, particularly during product launches.

“We are excited to have completed the first GMP batch at our Portsmouth facility,” said Stefan Egli, Head of the Mammalian Business Unit at Lonza. “This milestone is a testament to our commitment to delivering industry-leading manufacturing services to our customers, highlighting our continued efforts to support our customers’ needs across their product lifecycle and meet growing market demand for the launch scale.”

The Portsmouth site is designed to complement Lonza’s existing commercial mammalian manufacturing, with larger-scale facilities offering 6,000L and 20,000L capacities. The new 2,000L asset focuses on innovative therapies, including those targeting rare diseases, offering the flexibility required for efficient product launches and lifecycle management. The combination of these advanced production capabilities ensures that Lonza can support its clients across their entire product lifecycle, providing a reliable and scalable route to market for a wide range of biologics.